Volume 27 - Issue 6 - June, 2015

Volume Number: 
27
Issue Number: 
6
Journal Date: 
June, 2015
Supplement: 
uniqueID: 
1
Publish Date: 
06/01/2015 - 19:46

Silk Road Medical Appoints Andrew Davis as Executive Vice President of Global Sales

SUNNYVALE, Calif., May 28, 2015 /PRNewswire/ -- Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the appointment of Andrew (Andy) Davis to the position of Executive Vice President of Global Sales. In this new role, Andy will assemble a sales organization and lead the company's commercialization efforts for the TransCarotid Artery Revascularization (TCAR) procedure with the ENROUTE Transcarotid Neuroprotection System (NPS) and the ENROUTE Transcarotid Stent System.

Journal of Invasive Cardiology Launches Ahead of Print Section

MALVERN, Pennsylvania: The Journal of Invasive Cardiology is pleased to announce the launch of a new Ahead of Print (AOP) section on the Journal’s website at www.invasivecardiology.com. The Journal’s ability to post articles Ahead of Print will facilitate shorter time-to-publication and the dissemination of timely information from the dynamic field of interventional cardiology.

Beaumont Offers New Device to Help Patients With Right-Side Heart Failure

May 21, 2015 — Beaumont Hospital, Royal Oak, Michigan, is one of the first centers in the United States to use a new minimally invasive heart pump designed to provide temporary support for patients with severe right-side heart failure.

The Impella RP device provides circulatory assistance for up to 14 days for patients who develop severe right heart failure following heart attack, open-heart surgery, heart transplantation or left ventricular assist device implantation.

New Data Further Emphasize the Clinical Benefits of St. Jude Medical’s OCT Technology

In two new late-breaking clinical trials, OCT imaging guidance was found to influence clinical decision-making and support improved patient outcomes during PCI

Opsens announces first use of its FFR products by Dr. Nico Pijls

QUEBEC CITY, May 20, 2015 /CNW Telbec/ - Opsens inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the first use of the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), by Dr. Nico Pijls in Eindhoven, the Netherlands. Opsens' FFR products are designed to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

SAPIEN 3 Valve Again Demonstrates Low Mortality, Excellent 30-Day Outcomes In Intermediate-Risk Patients

PARIS, May 20, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks.  These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States.

Data Presented on Orsiro Hybrid Drug-Eluting Stent at EuroPCR 2015 Highlights Safety and Efficacy in High-Risk Patients

Experts at BIOTRONIK-Sponsored Symposium Discussed Orsiro’s Performance in Difficult Cases as well as Coming Developments in Percutaneous Coronary Intervention


Back to top